Safety and efficacy of anticoagulation for secondary stroke prevention in atrial fibrillation patients: The AMADEUS trial

D.A. Lane, P.W. Kamphuisen, P. Minini, H.R. Buller, G.Y.H. Lip

Research output: Contribution to journalArticleAcademicpeer-review


ackground: Patients with atrial fibrillation (AF) and previous ischemic stroke are at high risk of recurrent stroke, but are also perceived to be at increased bleeding risk while treated with anticoagulants. Methods: Post-hoc analyses examined the efficacy and safety of anticoagulation of 4576 AF patients [mean (SD) age 70.1 (9.1) years, 66.5% men] enrolled in the AMADEUS trial, randomised to receive either subcutaneous idraparinux (2.5mg weekly, n=2283) or dose-adjusted vitamin K antagonists (VKAs; INR 2.0- 3.0, n=2293). Results: 580 (12.7%) patients [idraparinux n=271; VKAs, n=309] experienced a previous ischaemic stroke. Previous ischemic stroke patients, were less likely to receive VKA prior to randomisation compared to non-ischemic stroke patients [68.6% vs. 77.0%; p
Original languageEnglish
Pages (from-to)923-924
Number of pages2
JournalEuropean Heart Journal
Publication statusPublished - 1-Sep-2010


  • idraparinux
  • antivitamin K
  • acetylsalicylic acid
  • ticlopidine
  • anticoagulant agent
  • patient
  • cardiology
  • cerebrovascular accident
  • prevention
  • anticoagulation
  • heart atrium fibrillation
  • safety
  • society
  • risk
  • brain ischemia
  • bleeding
  • stroke patient
  • randomization
  • international normalized ratio
  • post hoc analysis
  • brain hemorrhage

Cite this